

elranatamab-bcmm (Elrexio®)

Medical Benefit Drug Policy

Place of Service

- Hospital Administration
- Infusion Center Administration
- Office Administration
- Outpatient Facility Administration

Drug Details

USP Category: ANTINEOPLASTICS

Mechanism of Action: Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager

HCPCS:

- Through 3/31/2024: C9165 per 1 mg
- Effective 4/1/2024 and after: J1323 per 1 mg

How Supplied:

NDC(s):

- 0069-4494-02: 76 mg/1.9 mL (40 mg/mL) single-dose vial
- 0069-2522-02: 44 mg/1.1 mL (40 mg/mL) single-dose vial

Condition(s) listed in policy (*see coverage criteria for details*)

- Multiple myeloma

The following condition(s) require Prior Authorization/Preservice:

Multiple myeloma

1. Being used as single agent therapy, AND
2. Patient has received at least four prior therapies that include the use of all of the following:
 - a. An anti-CD38 monoclonal antibody (e.g., Darzalex, Sarclisa), and
 - b. A proteasome inhibitor (e.g., Velcade, Kyprolis, Ninlaro), and
 - c. An immunomodulatory agent (e.g., Pomalyst, Revlimid, Thalomid)

Covered Doses:

Dosing Schedule	Day	Dose	
Step-up Dosing Schedule	Day 1	Step-up dose 1	12 mg
	Day 4	Step-up dose 2	32 mg
	Day 8	First treatment dose	76 mg
Weekly Dosing Schedule	One week after first treatment dose and	Subsequent treatment doses	76 mg

elranatamab-bcmm (Elrexio®)

	weekly thereafter through week 24		
Every 2 Weeks Dosing Schedule *Responders only week 25 onward	Week 25 and every 2 weeks thereafter	Subsequent treatment doses	76 mg

Coverage Period:
Indefinite

References

1. AHFS®. Available by subscription at <http://www.lexi.com>
2. DrugDex®. Available by subscription at <http://www.micromedexsolutions.com/home/dispatch>
3. Elrexio (elranatamab-bcmm). [Prescribing information]. Pfizer, Inc.; 8/2023.

Review History

- Date of Last Annual Review: 11/29/2023
 Date of last revision: 4/3/2024
 Changes from previous policy version:
- Effective 4/1/2024 and after: J1323 per 1 mg

*Blue Shield of California Medication Policy to Determine Medical Necessity
 Reviewed by P&T Committee*